Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011583 | 0.84 | LMNA (0.43) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL2533923 | 0.84 | KCNH2 (0.46) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL14251568 | 0.83 | LMNA (0.39) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL27580125 | 0.79 | MTNR1B (0.42) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL11070962 | 0.79 | KDM4E (0.44) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL13652181 | 0.78 | KDM4E (0.49) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL15961002 | 0.78 | KCNH2 (0.41) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL7100441 | 0.76 | MTNR1B (0.40) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL14250570 | 0.75 | PTGS1 (0.42) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL6267955 | 0.75 | KCNH2 (0.48) | LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721034-B1 | N-HETEROTRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2016-07-20 | — | — | EP | disclosed |
| US-9321788-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2016-04-26 | — | — | US | disclosed |
| US-9120822-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-01 | — | — | US | disclosed |
| CN-102666548-B | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG | 2015-07-15 | — | — | CN | disclosed |
| US-20150072975-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG | 2015-03-12 | — | — | US | disclosed |
| US-8927541-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| US-20140235855-A1 | Tricyclic Antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2014-08-21 | — | — | US | disclosed |
| EP-2721034-A1 | TRICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2014-04-23 | — | — | EP | disclosed |
| EP-2513115-B1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012171860-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2012-12-20 | — | — | WO | disclosed |
| EP-2513115-A1 | TRICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-20120245345-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2012-09-27 | — | — | US | disclosed |
| WO-2011073378-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245345-A1 | TRICYCLIC ANTIBIOTICS | CBR1, CBR3, C1S | LMNA 4019/4885KDM4E 3896/4885HTR1A 1136/4885 |
| US-20140235855-A1 | Tricyclic Antibiotics | CBR1, CYP2S1, C1S | LMNA 2779/4885KDM4E 4454/4885HTR1A 670/4885 |
| US-20150072975-A1 | TRICYCLIC ANTIBIOTICS | TREH, MRPL21, SPOUT1 | LMNA 3459/4885KDM4E 2900/4885HTR1A 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.